{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:38:31Z","timestamp":1787683111011,"version":"build-2784847793"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI110769, R01AI149502"],"award-info":[{"award-number":["R01AI110769, R01AI149502"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM103516"],"award-info":[{"award-number":["P20GM103516"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001159","name":"Hawaii Community Foundation","doi-asserted-by":"publisher","award":["MedRes-2022-0000 0789"],"award-info":[{"award-number":["MedRes-2022-0000 0789"]}],"id":[{"id":"10.13039\/100001159","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The four serotypes of dengue virus (DENV1-4) are the leading cause of arboviral diseases in humans. Currently, developing a safe and effective DENV vaccine remains a challenge. Previously we reported potently neutralizing human monoclonal antibodies (mAbs) preferentially recognize mature DENV particles, on which there is limited access to the fusion loop (FL) epitope and no premembrane (prM) protein. As FL and prM antibodies are weakly- or non-neutralizing and contribute to antibody-dependent enhancement, mature DENV particles represent an ideal DENV vaccine candidate. Several inactivated flavivirus vaccines, generated using formalin, ultraviolet or other inactivation methods, have progressed through preclinical and clinical studies. Little is known about how different inactivation methods affect viral epitopes and the quality of antibodies induced.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We investigated epitopes on Tween 20-inactivated mature DENV1 particles by testing a panel of well-characterized human mAbs and membrane integrity by sucrose-gradient ultracentrifugation and protein K digestion. We examined the mechanisms of Tween 20 inactivation by measuring RNA copy numbers, virus binding to cells and acid exposure, and antibody responses induced by Tween 20-inactivated mature DENV1 particles in mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Tween 20 inactivation better preserved the epitopes recognized by potently neutralizing mAbs compared with other methods. Sucrose-gradient ultracentrifugation and protein K digestion revealed no disruption of membrane integrity by Tween 20. Mechanistically, Tween 20 treatment caused reduced virus binding to cells and RNA degradation, which was reverted by pre-treatment with RNAseOUT, suggesting the involvement of extracellular RNase, and prevented the envelope protein conformational changes induced by acid exposure. Moreover, Tween 20-inactivated mature DENV1 particles induced a neutralizing antibody response to all four DENV serotypes characterized by competition with several potently neutralizing mAbs and limited recognition of FL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results suggest that Tween 20-inactivated mature particles are a promising strategy for DENV vaccine development.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1626823","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:27:07Z","timestamp":1757482027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mature dengue virus particles inactivated by a non-ionic detergent retain quaternary neutralizing epitopes and induce potent neutralizing antibodies"],"prefix":"10.3389","volume":"16","author":[{"given":"Wen-Yang","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore C.","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wrammert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwisa","family":"Dejnirattisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amonrat","family":"Jumnainsong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthathip","family":"Mongkolsapaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Screaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James E.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Kung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","article-title":"Dengue infection","volume":"2","author":"Guzman","year":"2016","journal-title":"Nat RevDis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(23)02576-X","article-title":"Dengue","volume":"403","author":"Paz-Bailey","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","article-title":"Dengue vaccine: WHO position paper - September 2018","volume":"93","year":"2018","journal-title":"Weekly Epidemiol Rec"},{"key":"B7","unstructured":"Dengue, Notice about Dengvaxia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomized, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"B10","unstructured":"Takeda Announces Voluntary Withdrawal of U.S. Biologics License Application (BLA) for Dengue Vaccine Candidate TAK-003"},{"key":"B11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","article-title":"Flaviviruses","volume-title":"Fields virology","author":"Pierson","year":"2013"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature02165","article-title":"Structure of the dengue virus envelope protein after membrane fusion","volume":"427","author":"Modis","year":"2004","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells","volume":"75","author":"Crill","year":"2001","journal-title":"J Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","first-page":"139ra83","DOI":"10.1126\/scitranslmed.3003888","article-title":"The structural basis for serotype-specific neutralization of dengue virus by a human antibody","volume":"4","author":"Teoh","year":"2012","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8651","article-title":"Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"Fibriansah","year":"2015","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001188","article-title":"In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection","volume":"5","author":"de Alwis","year":"2011","journal-title":"PloS Negl Trop Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00871-13","article-title":"High avidity and potent neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection","volume":"87","author":"Tsai","year":"2013","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1128\/JVI.02273-12","article-title":"Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop","volume":"87","author":"Costin","year":"2013","journal-title":"J Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00696-10","article-title":"Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles","volume":"84","author":"Junjhon","year":"2010","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2011.75","article-title":"Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres","volume":"12","author":"Plevka","year":"2011","journal-title":"EMBO Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(02)00660-8","article-title":"Structure of dengue virus: implications for flavivirus organization, maturation, and fusion","volume":"108","author":"Kuhn","year":"2002","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg270","article-title":"Structures of immature flavivirus particles","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812055115","article-title":"Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies","volume":"116","author":"Raut","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000060","article-title":"Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization","volume":"4","author":"Nelson","year":"2008","journal-title":"PLoS Pathog"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2008.08.004","article-title":"Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development","volume":"4","author":"Pierson","year":"2008","journal-title":"Cell Host Microbe"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00556-18","article-title":"Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy for dengue vaccine","volume":"92","author":"Tsai","year":"2018","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-018-0283-7","article-title":"A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions","volume":"4","author":"Goo","year":"2019","journal-title":"Nat Microbiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/265739a0","article-title":"Antibody-enhanced dengue virus infection in primate leukocytes","volume":"265","author":"Halstead","year":"1977","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv Virus Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703498104","article-title":"Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention","volume":"104","author":"Goncalvez","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000718","article-title":"Immature dengue virus: a veiled pathogen","volume":"6","author":"Rodenhuis-Zybert","year":"2010","journal-title":"PLoS Pathog"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1004386","DOI":"10.1371\/journal.ppat.1004386","article-title":"Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera","volume":"10","author":"de Alwis","year":"2014","journal-title":"PLoS Pathog"},{"key":"B39","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/v15040860","article-title":"A perspective on current flavivirus vaccine development: a brief review","volume":"15","author":"Dutta","year":"2023","journal-title":"Viruses"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-040717-051127","article-title":"Zika virus vaccine development: progress in the face of new challenges","volume":"70","author":"Diamond","year":"2019","journal-title":"Annu Rev Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.040","article-title":"A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available","volume":"32","author":"Ishikawa","year":"2014","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3390\/v15040813","article-title":"Recent Advancements in Mosquito-borne flavivirus vaccine development","volume":"15","author":"Wu","year":"2023","journal-title":"Viruses"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-022-1625-y","article-title":"Current status and perspectives on vaccine development against dengue virus infection","volume":"60","author":"Park","year":"2022","journal-title":"J Microbiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38970.034","article-title":"Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody","volume":"7","author":"Shen","year":"2018","journal-title":"Elife"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.10.085","article-title":"Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine","volume":"30","author":"Porter","year":"2012","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/vaccines10060834","article-title":"Nucleic acid vaccine platform for dengue and zika flaviviruses","volume":"10","author":"Taslem Mourosi","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23802","article-title":"Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines","volume":"9","author":"Amicizia","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3201\/eid1901.120458","article-title":"Vaccination and tick-borne encephalitis, central Europe","volume":"19","author":"Heinz","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.001","article-title":"Vaccine failures after active immunisation against tick-borne encephalitis","volume":"28","author":"Andersson","year":"2010","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","article-title":"Japanese encephalitis vaccine: recommendations of the advisory committee on immunization practices","volume":"68","author":"Hills","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico","volume":"98","author":"Diaz","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33106-9","article-title":"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials","volume":"391","author":"Modjarrad","year":"2018","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0004167","DOI":"10.1371\/journal.pntd.0004167","article-title":"Formalin inactivation of Japanese encephalitis virus vaccine alters the antigenicity and immunogenicity of a neutralization epitope in envelope protein domain III","volume":"9","author":"Fan","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide\u2013based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12414","article-title":"Riboflavin and ultraviolet light: impact on dengue virus infectivity","volume":"111","author":"Faddy","year":"2016","journal-title":"Vox Sang"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4161\/hv.25602","article-title":"Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4\u2019-aminomethyl-trioxsalen) is highly immunogenic in mice","volume":"9","author":"Raviprakash","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.077","article-title":"Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys","volume":"29","author":"Maves","year":"2011","journal-title":"Vaccine"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2174\/1567201815666180503122829","article-title":"Polysorbate surfactants as drug carriers: Tween 20-Amphotericin B conjugates as anti-fungal and anti-leishmanial agents","volume":"15","author":"Ravichandran","year":"2018","journal-title":"Curr Drug Deliv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.8.3044-3046.2002","article-title":"Inactivation of West Nile virus during serologic testing and transport","volume":"40","author":"Mayo","year":"2002","journal-title":"J Clin Microbiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jviromet.2008.12.003","article-title":"Laboratory safe detection of nucleocapsid protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA","volume":"157","author":"Jansen van Vuren","year":"2009","journal-title":"J Virol Methods"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw289","article-title":"Inactivation of Zaire ebolavirus variant Makona in human serum samples analyzed by enzyme-linked immunosorbent assay","volume":"214","author":"Cutts","year":"2016","journal-title":"J Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.virol.2016.06.022","article-title":"Enhancing dengue virus maturation using a stable furin over-expressing cell line","volume":"497","author":"Mukherjee","year":"2016","journal-title":"Virology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.str.2018.05.006","article-title":"Refinement and analysis of the mature Zika virus cryo-EM structure at 3.1 \u00c5 resolution","volume":"26","author":"Sevvana","year":"2018","journal-title":"Structure"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"Priyamvada","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature20564","article-title":"Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice","volume":"540","author":"Sapparapu","year":"2016","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01690-13","article-title":"Aluminum hydroxide influences not only the extent but also the fine specificity and functional activity of antibody responses to tick-borne encephalitis virus in mice","volume":"87","author":"Zlatkovic","year":"2013","journal-title":"J Virol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00208-0","article-title":"A purified inactivated Japanese encephalitis virus vaccine made in Vero cells","volume":"19","author":"Srivastava","year":"2001","journal-title":"Vaccine"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.03580-14","article-title":"Mechanisms of methods for hepatitis C virus inactivation","volume":"81","author":"Pfaender","year":"2015","journal-title":"Appl Environ Microbiol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.610428","article-title":"Highly conserved residues in the helical domain of dengue virus type 1 precursor membrane protein are involved in assembly, precursor membrane (prM) protein cleavage, and entry","volume":"289","author":"Hsieh","year":"2014","journal-title":"J Biol Chem"},{"key":"B72","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0166-0934(01)00280-4","article-title":"Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1\u20134 using conserved and serotype-specific 3\u2019 noncoding sequences","volume":"95","author":"Houng","year":"2001","journal-title":"J Virol Methods"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02041-16","article-title":"Mapping the human memory B Cell and serum neutralizing antibody responses to dengue virus serotype 4 infection and vaccination","volume":"91","author":"Nivarthi","year":"2017","journal-title":"J Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002451","article-title":"Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases","volume":"7","author":"Lai","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815432116","article-title":"Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope","volume":"116","author":"Long","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00757-13","article-title":"Structural changes in dengue virus when exposed to a temperature of 37 \u00b0C","volume":"87","author":"Fibriansah","year":"2013","journal-title":"J Virol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"14339","DOI":"10.1038\/ncomms14339","article-title":"Conformational changes in intact dengue virus reveal serotype-specific expansion","volume":"8","author":"Lim","year":"2017","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nm1240","article-title":"Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus","volume":"11","author":"Oliphant","year":"2005","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210236","article-title":"Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease","volume":"218","author":"Agudelo","year":"2021","journal-title":"J Exp Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00008-18","article-title":"Mouse and human monoclonal antibodies protect against infection by multiple genotypes of Japanese encephalitis virus","volume":"9","author":"Fernandez","year":"2018","journal-title":"mBio"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:27:09Z","timestamp":1757482029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2025.1626823"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1626823","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1626823"}}